Reasons for Jong Kim’s Shares Sale of Inovio Pharmaceuticals, Inc. (INO)’s Stock; Chemed (CHE) Shorts Increased By 15.39%

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Logo

Chemed Corp (NYSE:CHE) had an increase of 15.39% in short interest. CHE’s SI was 1.05 million shares in April as released by FINRA. Its up 15.39% from 914,000 shares previously. With 96,400 avg volume, 11 days are for Chemed Corp (NYSE:CHE)’s short sellers to cover CHE’s short positions. The SI to Chemed Corp’s float is 6.79%. The stock increased 0.11% or $0.3 during the last trading session, reaching $283.02. About 90,576 shares traded. Chemed Corporation (NYSE:CHE) has risen 48.33% since April 14, 2017 and is uptrending. It has outperformed by 36.78% the S&P500.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.67’s average target is 189.92% above currents $5.06 stock price. Inovio Pharmaceuticals had 41 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Buy” rating by Maxim Group on Wednesday, August 9. As per Thursday, November 9, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Tuesday, January 23 with “Buy” rating. H.C. Wainwright maintained the shares of INO in report on Wednesday, March 21 with “Buy” rating. The rating was maintained by H.C. Wainwright on Tuesday, February 13 with “Buy”. The firm earned “Buy” rating on Tuesday, November 28 by H.C. Wainwright. On Friday, October 6 the stock rating was initiated by Citigroup with “Buy”. As per Tuesday, September 12, the company rating was maintained by H.C. Wainwright. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Buy” rating by H.C. Wainwright on Wednesday, October 25. The firm has “Hold” rating given on Friday, August 14 by Zacks.

Company insider, Jong Kim, Chief Executive Officer of Inovio Pharmaceuticals Inc sold a total of 211,250 shares of the firm, which is calculated based on a stock price of $5.1 per each share. Currently, Mr. Jong, has ownership of 4.15 million shares, which accounts for 4.57% of Inovio Pharmaceuticals Inc’s market cap.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $458.95 million. The Company’s SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

Investors sentiment is 2 in Q4 2017. Its the same as in 2017Q3. It is flat, as 0 investors sold Inovio Pharmaceuticals, Inc. shares while 1 reduced holdings. only 1 funds opened positions while 1 raised stakes. 44,744 shares or 7.51% more from 41,620 shares in 2017Q3 were reported. Pnc Fin Svcs Group Inc Incorporated Inc holds 0% of its portfolio in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) for 1,000 shares. Neville Rodie Shaw has 10,000 shares for 0.03% of their portfolio. Parametric Portfolio Assoc Limited Liability Company invested in 0% or 19,344 shares. Shapiro Capital Lc reported 0.01% in Inovio Pharmaceuticals, Inc. (NASDAQ:INO). First Dallas Securities has invested 0.07% of its portfolio in Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

The stock decreased 1.94% or $0.1 during the last trading session, reaching $5.06. About 790,433 shares traded. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 24.44% since April 14, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Chemed Corporation provides hospice and palliative care services in the United States. The company has market cap of $4.57 billion. It operates through two divisions, VITAS and Roto-Rooter. It has a 48.3 P/E ratio. The firm offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Investors sentiment decreased to 0.96 in Q4 2017. Its down 0.08, from 1.04 in 2017Q3. It fall, as 18 investors sold Chemed Corporation shares while 94 reduced holdings. 49 funds opened positions while 58 raised stakes. 14.86 million shares or 3.45% less from 15.40 million shares in 2017Q3 were reported. Parametrica Mngmt invested in 0.24% or 1,587 shares. Sawgrass Asset Limited Liability Com reported 0.03% stake. Sei Investments Company has invested 0.02% in Chemed Corporation (NYSE:CHE). Captrust Finance Advisors invested in 134 shares. Private Trust Na reported 2,176 shares. American invested 0.01% in Chemed Corporation (NYSE:CHE). Tompkins Fincl Corp holds 607 shares or 0.03% of its portfolio. Cambridge Invest Rech Incorporated holds 0% of its portfolio in Chemed Corporation (NYSE:CHE) for 1,271 shares. Gamco Investors Incorporated Et Al stated it has 0.76% in Chemed Corporation (NYSE:CHE). Gam Hldg Ag reported 2,967 shares stake. 40,904 are held by Wellington Group Ltd Liability Partnership. 226 are owned by Greenleaf Trust. Los Angeles Capital Management & Equity Rech accumulated 16,679 shares. The California-based Eqis Mngmt has invested 0.06% in Chemed Corporation (NYSE:CHE). Spark Inv Mgmt Limited Liability stated it has 1,800 shares.

Since October 30, 2017, it had 0 buys, and 5 selling transactions for $4.34 million activity. Dallob Naomi C sold $269,850 worth of stock. SAUNDERS DONALD E sold $117,485 worth of stock or 450 shares. 10,000 shares were sold by MCNAMARA KEVIN J, worth $2.23M on Monday, October 30.

Among 3 analysts covering Chemed (NYSE:CHE), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Chemed had 17 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Hold” on Friday, September 1. The stock of Chemed Corporation (NYSE:CHE) has “Sector Perform” rating given on Monday, May 2 by RBC Capital Markets. RBC Capital Markets maintained it with “Hold” rating and $20800 target in Wednesday, July 5 report. The rating was maintained by Oppenheimer with “Outperform” on Tuesday, September 22. The stock of Chemed Corporation (NYSE:CHE) has “Outperform” rating given on Monday, October 26 by Oppenheimer. The firm has “Sector Perform” rating given on Tuesday, November 1 by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Monday, October 26 with “Sector Perform”. The company was maintained on Thursday, October 26 by KeyBanc Capital Markets. On Tuesday, July 25 the stock rating was maintained by Oppenheimer with “Buy”. RBC Capital Markets maintained Chemed Corporation (NYSE:CHE) on Sunday, July 30 with “Hold” rating.

Chemed Corporation (NYSE:CHE) Institutional Positions Chart